Safety and Efficacy of AL-53817 Nasal Spray Solution
Completed · Phase 1 · Has a placebo group
Conditions studied: Nasal Allergies, Allergies
In brief
The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
Key facts
- Study ID
- NCT01454505
- Run by
- Alcon Research
- People needed
- 110
- Starts
- 2011-10-01
- Expected to finish
- 2012-03-01
- Last updated by the study team
- 2013-05-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Alcon Call Center for Trial Locations — Fort Worth, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.